Through Medication Therapy Management, a pharmacist will be able to recognize indications of potential opioid abuse, explained Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare.
Through Medication Therapy Management, a pharmacist will be able to recognize indications of potential opioid abuse, explained Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare.
Transcript
How can Medication Therapy Management be used to address opioid misuse?
In the course of an MTM [Medication Therapy Management] consultation or a comprehensive medication review, a pharmacist will review all of the medications the patient is taking, and that will also include, in better MTM programs, over-the-counter medications and vitamin supplements. In the course of looking at all of the medications, which will include opioids, a pharmacist will be able to see trends, with respect to the opioids, such as multiple refills, different prescribers writing prescriptions for opioids, and filling prescriptions across state lines. These are all indications of potential abuse.
Tabula Rasa HealthCare has announced their Optimized Opioid Solution. How will this solution identify and prevent opioid misuse?
TRHC looks at medications in the MTM context very differently than other MTM companies. Rather than looking at single drug to drug interactions, Tabula Rasa looks at accumulative, simultaneous multi-drug interactions. So, we’re looking at the entire cocktail of medications. What this means with respect to opioids is that a patient who’s taking opioids and other medications, there may be interactions between those other medications and the opioid that can lead to serious problems.
The opioid could provide more analgesic impact to the body than the prescriber would expect, or it might provide less, which also causes serious problems. So, by identifying the impact of the other medications that a patient is taking along with the opioid, we can get a head start on risk associated with unintentional misuse of opioids that lead to potential abuse.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More